COVID-19 Immunology

The Quanterix Simoa technology enables researchers to measure baseline levels of important cytokines and chemokines (such as IL-6, TNFα, IL-8 and even low abundance IFNα and IL1β) well above limits of quantification and directly in blood. We invite you to watch the webinar below to learn more:



Measuring early levels of these biomarkers during acute infection will deepen our understanding of cytokine storm onset and related cardiopulmonary and neurological damage. Simoa allows measurement of trace levels of IFNα, which enables separation of bacterial from viral infections, characterization of lupus samples and now following COVID-19 patients IFNα profile and assess type I interferon treatment options. Listen to key opinion leaders discussing their views on circulating cytokines as predictive biomarkers for COVID-19 severity, early viral load quantification based on viral proteins and early measurement of IgM, IgG and IgA for seroprevalence studies.

Supporting Documents

Studying the Key Role of Inflammation in Disease Progression and Severity
Studying the Key Role of Inflammation in Disease Progression and Severity

  • Up-regulation and suppression of Type I and Type II interferons (IFNα, IFNγ) as early predictors of disease severity
  • Pro-inflammatory cytokines (GM-CSF, IL-2, IL-6, IL-10, IL-12p70, TNFα) for early detection of imbalanced Th1 and Th2 response and risk for severe cytokine release
  • Biomarkers of chronic airway inflammatory disease (IL-4, IL-5, IL-13)
  • Airway remodeling (MMP-9) in virus-induced chronic pulmonary disease

Access Now
Characterizing Links between Viral Infection and Neurological Manifestations
Characterizing Links between Viral Infection and Neurological Manifestations

  • The role of circulating and CNS levels of chemokines (Eoxtaxin, IP-10, MCP-1) in neuroinflammation
  • Multiplex measurement of serum and plasma-based biomarkers of neurodegeneration (NF-l, GFAP, UCH-L1, tau)
  • Detection of biomarkers from dried blood spots enables use of remote sample collection protocols

Access Now
Measuring the Earliest Biomarkers of Myocardial Injury and Risk of Acute and Chronic Cardiac Disease
Measuring the Earliest Biomarkers of Myocardial Injury and Risk of Acute and Chronic Cardiac Disease

  • Ultra-sensitive measurement of changes in baseline levels of cardiac troponin I (cTnI) for determining risk of Acute Coronary Syndrome
  • Detection of natriuretic peptides (NT-proBNP) in monitoring chronic cardiac disease in COVID-19

Access Now
Developing New Ultra-Sensitive Assays for Viral Detection and Host Response
Developing New Ultra-Sensitive Assays for Viral Detection and Host Response

  • Quanterix’ unique homebrew ultrasensitive assay development capabilities provide the flexibility for researchers to develop singleplex and multiplex custom Simoa assays
  • Viral protein detection with PCR-level sensitivity with the speed and convenience of immunoassays
  • Serological assays to for characterizing host immune response, surveillance and vaccine development
  • Direct detection of nucleic acids using Simoa homebrew assay reagents to enable measurement of pathogen DNA and host miRNA biomarker levels without extraction or amplification

Access Now
Ready to take the next step in accessing a highly sensitive and accurate multiplex test to monitor the immune response to viral infection?
Email us!

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more